Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Samir Hanash

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4210-1593; OpenAlex author ID A5040156444. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
125
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 6 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 25

  1. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  2. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adeno… Co-author DOI 10.64898/2026.10.05.756824↗
  3. Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Co-author DOI 10.1016/j.canlet.2025.217450↗
  4. Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progress… Co-author DOI 10.1158/1078-0432.ccr-24-2931↗
  5. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Co-author DOI 10.1016/j.canlet.2024.217245↗
  6. Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer. Co-author DOI 10.1093/clinchem/hvad186↗
  7. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  8. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  9. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an ea… Co-author DOI 10.1101/2023.08.14.553002↗
  10. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Co-author DOI 10.1016/j.molmet.2021.101426↗
  11. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Last author DOI 10.1053/j.gastro.2020.11.052↗
  12. Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN. Co-author DOI 10.1158/1055-9965.epi-20-0161↗
  13. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Last author DOI 10.1200/po.19.00330↗
  14. Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12030746↗
  15. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Co-author DOI 10.1016/j.cell.2019.07.008↗
  16. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Last author DOI 10.1038/s41467-018-08109-6↗
  17. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
  18. Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor. Co-author DOI 10.1039/c9sc00283a↗
  19. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Last author DOI 10.1093/jnci/djy126↗
  20. Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers. Co-author DOI 10.3389/fonc.2019.00115↗
  21. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx542↗
  22. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx004↗
  23. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Last author DOI 10.1093/jnci/djw266↗
  24. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0152300↗
  25. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1093/jnci/djv132↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 22 shared papers, 2015–2026 · strength 2.52
  2. Johannes Francois Fahrmann · 14 shared papers, 2019–2026 · strength 2.07
  3. Jody V. Vykoukal · 12 shared papers, 2019–2026 · strength 1.74
  4. Ehsan Irajizad · 11 shared papers, 2020–2026 · strength 1.73
  5. Michele Yip-Schneider · 6 shared papers, 2019–2025 · strength 0.91
  6. Jianjun Zhang · 6 shared papers, 2019–2025 · strength 0.91
  7. Michela Capello · 11 shared papers, 2015–2022 · strength 0.82
  8. Ricardo A. Léon-Letelier · 4 shared papers, 2023–2026 · strength 0.73
  9. Christian Max Schmidt · 5 shared papers, 2019–2025 · strength 0.68
  10. Yihui Chen · 4 shared papers, 2022–2026 · strength 0.65
  11. Matthew H. G. Katz · 9 shared papers, 2015–2022 · strength 0.58
  12. Brian Matthew Wolpin · 4 shared papers, 2021–2026 · strength 0.56
  13. Florencia M. McAllister · 3 shared papers, 2019–2026 · strength 0.50
  14. Randall E. Brand · 5 shared papers, 2017–2024 · strength 0.46
  15. Jason B. Fleming · 6 shared papers, 2015–2022 · strength 0.46
  16. Ziding Feng · 4 shared papers, 2019–2026 · strength 0.45
  17. Eugene Jon Koay · 2 shared papers, 2026 · strength 0.44
  18. Riccardo Ballarò · 2 shared papers, 2025–2026 · strength 0.40
  19. Ana Babić · 3 shared papers, 2021–2024 · strength 0.35
  20. Andrea J. Bullock · 3 shared papers, 2021–2024 · strength 0.35
  21. Thomas E. Clancy · 3 shared papers, 2021–2024 · strength 0.35
  22. Kimmie Ng · 3 shared papers, 2021–2024 · strength 0.35
  23. Michael D. Kluger · 3 shared papers, 2021–2024 · strength 0.35
  24. Kunal Jajoo · 3 shared papers, 2021–2024 · strength 0.35
  25. John A. Chabot · 3 shared papers, 2021–2024 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.